Nano-X Imaging Ltd. (NNOX) AI Stock Analysis

Nano-X Imaging Ltd. specializes in advancing tomographic imaging technology through its digital X-ray source. The company focuses on developing and commercializing the Nanox.ARC, a medical imaging system that integrates a proprietary digital micro-electro-mechanical systems semiconductor cathode. Beyond hardware, it provides software solutions such as Nanox.CLOUD, a subscription-based platform facilitating medical screening services, and Nanox.MARKETPLACE, which links imaging facilities with radiologists for remote diagnostic interpretation. Nano-X also creates artificial intelligence applications for hospitals, health maintenance organizations, and insurers to detect and predict conditions like osteoporosis and cardiovascular disease from computed tomography scans. Founded in 2011, the company is headquartered in Neve Ilan, Israel.

Nano-X has grown its top line from $1.3M in FY2021 to $13.0M in FY2025, representing a 77.8% four-year revenue CAGR. Annual revenue rose 557.8% in FY2022 to $8.6M, 15.5% in FY2023 to $9.9M, 13.9% in FY2024 to $11.3M, and 15.4% in FY2025. However, margins remain severely negative. The company recorded a gross margin of -98.2% and an operating margin of -466.2% in FY2025, alongside a net loss of -$75.0M. For the trailing twelve months ended June 30, 2026, revenue stood at $15.6M, supported by quarterly revenue growth of 36.7% year-over-year. Operating margin for the trailing twelve months was -355.3%, and diluted EPS was -$1.72.

As of June 30, 2026, Nano-X held $31.0M in cash and short-term investments against total debt of $7.7M, leaving a net cash balance of $23.3M. The company maintains a current ratio of 2.84 and a debt-to-equity ratio of 0.11, with total shareholders' equity of $72.5M and total assets of $91.2M. Cash burn remains a key factor, as FY2025 operating cash flow was -$40.8M, free cash flow was -$45.0M, and capital expenditures reached $4.2M. Over five years, the company's share count increased 34.0%.

Nano-X trades at a price-to-sales multiple of 2.3x and an enterprise value-to-revenue ratio of 2.0x, both below the median of its US-listed Healthcare peers at 4.1x sales. Its price-to-book ratio stands at 0.8x. At a market cap of $35.6M and an enterprise value of $31.5M, the stock closed at $0.45 on October 16, 2026, which is 73.8% below its 200-day average. Over the past year, the stock returned -89.0%, compared to a 16.8% return for the S&P 500 benchmark SPY, and over five years returned -98.0% versus 83.0% for SPY.

Wall Street coverage includes 2 Strong Buy ratings and 1 Hold rating, with no Buy, Sell, or Strong Sell recommendations. The mean price target is $4.13, representing an 812.6% premium over the last close of $0.45. For the fiscal year ending December 31, 2026, analysts estimate revenue of $22.3M and an EPS of -$0.60, representing a 6.2% EPS growth estimate. For the following fiscal year, 1 analyst projects revenue of $41.5M, reflecting 86.2% revenue growth, and an EPS of -$0.40. Nano-X beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 19, 2026.

This page is an AI-written research summary of Nano-X Imaging Ltd. (NNOX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NNOX income statement, NNOX balance sheet, NNOX key metrics, NNOX analyst forecast, NNOX chart. See the NNOX stock overview for the latest quote and news.